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Br J Clin Pharmacol. 2020;1–15.Aims: For vancomycin treatment in obese patients, there is no consensus on the
optimal dose that will lead to the pharmacodynamic target (area under the curve
400–700 mg h L−1). This prospective study quantifies vancomycin pharmacokinetics
in morbidly obese and nonobese individuals, in order to guide vancomycin dosing in
the obese.
Methods: Morbidly obese individuals (n = 20) undergoing bariatric surgery and
nonobese healthy volunteers (n = 8; total body weight [TBW] 60.0–234.6 kg)
received a single vancomycin dose (obese: 12.5 mg kg−1, maximum 2500 mg;
nonobese: 1000 mg) with plasma concentrations measured over 48 h (11–13 samples
per individual). Modelling, internal validation, external validation using previously pub-
lished data and simulations (n = 10.000 individuals, TBW 60–230 kg) were performed
using NONMEM.
Results: In a 3‐compartment model, peripheral volume of distribution and clearance
increased with TBW (both p < 0.001), which was confirmed in the external validation.
A dose of 35 mg kg−1 day−1 (maximum 5500 mg/day) resulted in a > 90% target
attainment (area under the curve > 400 mg h L−1) in individuals up to 200 kg, with
corresponding trough concentrations of 5.7–14.6 mg L−1 (twice daily dosing). For
continuous infusion, a loading dose of 1500 mg is required for steady state on day 1.
Conclusion: In this prospective, rich sampling pharmacokinetic study, vancomycin
clearance was well predicted using TBW. We recommend that in obese individuals
without renal impairment, vancomycin should be dosed as 35 mg kg−1 day−1 (maxi-
mized at 5500 mg/day). When given over 2 daily doses, trough concentrations of
5.7–14.6 mg L−1 correspond to the target exposure in obese individuals.
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What is already known about this subject
• Obesity can dramatically impact the pharmacokinetics of
antibiotics due to pathophysiological changes associated
with being overweight.
• For vancomycin, target 24‐h area under the curve values
for efficacy and toxicity have been well established for
Staphylococcus aureus infections and have been
incorporated in current guidelines.
• While there is ample evidence that both volume of
distribution and clearance increase in obese individuals,
there is conflicting evidence about how the vancomycin
dose should exactly be adapted in obese patients.
What this study adds
• This prospective, rich sampling pharmacokinetic study in
a wide range of body weights (60–235 kg) shows that
vancomycin volume of distribution and clearance can be
predicted by total body weight using a linear (volume of
distribution) or a power function with an exponent of
0.54 (clearance).
• We recommend that in order to optimize exposure in
obese individuals without renal impairment, vancomycin
should be dosed as 35 mg kg−1 day−1 (maximized at
5500 mg day−1).
• When divided over 2 doses day−1, trough concentrations
between 5.7 and 14.6 mg L−1 are sufficient to obtain the
target exposure.
• For continuous infusion regimens, we recommend a fixed
loading dose of 1500 mg for all body weights.
2 SMIT ET AL.1 | INTRODUCTION
Over recent decades, the worldwide prevalence of obesity (defined
as a body mass index [BMI] ≥30 kg m−2) has dramatically increased.1
Since 1975, the percentage of obese men and women has increased
from 3.2 and 6.4% to 10.8 and 14.9%, respectively. This corresponds
with 641 million individuals being obese worldwide. If this trend
continues, global obesity prevalence will reach 18–21% in 2025.1
Evidence suggests that these individuals are more prone to infec-
tions.2 As a consequence, clinicians are increasingly facing (severely)
obese patients requiring antibiotic treatment. It has been well
established that due to pathophysiological changes that are associ-
ated with overweight, such as an increased cardiac output, increase
in adipose tissue, changes in renal function and impacted metabolic
enzyme activity, the pharmacokinetics (PK) of drugs can be signifi-
cantly impacted, often requiring dose adaptations.3,4
Vancomycin is a glycopeptide antibiotic, introduced in clinical
practice over 60 years ago. Since then, vancomycin has become a
widely used agent predominantly for serious Gram‐positive infec-
tions and is considered first line treatment in methicillin‐resistant
Staphylococcus aureus infections.5 For these indications, the drug is
administered intravenously using intermittent or continuous infusion
regimens, preceded by a loading dose in the latter setting.6,7 Around
80% is excreted unchanged renally, mostly by glomerular filtration
but other (active) excretion pathways might also play an important
role.6 In S. aureus infections, vancomycin efficacy closely correlates
with a total 24‐h area under the curve (AUC24h) over the minimal
inhibitory concentration (MIC). Target AUC24h of vancomycin for
efficacy for this indication have been well defined in the clinical set-
ting, with thresholds of ≥345 to ≥451 mg h L−1 found over the
years, based on MICs up to 1 mg L−1.8-12 A comprehensive practice
guideline published in 2009 advocated an efficacy target of AUC24h/
MIC ≥400 mg h L−1.13 To reach this target with intermittent dose
regimens, a target steady state trough concentration of
15–20 mg L−1 was advised.13 There is, however, substantial evi-
dence from other populations that lower trough concentration
ranges might also be effective to reach the AUC24h target.
14,15 To
date, this has not been studied for the obese population. Regarding
vancomycin toxicity, 700 mg h L−1 was recently proposed as an
AUC24h upper limit for the first 48 h of treatment.
16 Another study
found an increasing risk of nephrotoxicity with steady state AUC24h
values over 1300 mg h L−1.17
With respect to dosing guidelines, according to the Food and
Drug Administration (FDA) drug label, vancomycin should be given
as a fixed dose of 2000 mg day−1 in adults with a normal renal func-
tion, without specific recommendations for obese patients.18 Since
the FDA‐regimen has been shown to result in suboptimal exposure
(AUC24h around 100–250 mg h L
−1) in normal weight adults, more
recent guidelines recommend 15–20 mg kg−1 every 8–12 h.13 This
rather broad dosing regimen is also recommended for obese
patients, thereby resulting in a large variability of dose regimens
used for obese individuals in clinical practice13 and is based on stud-
ies that are mostly performed with sparse data based on routinetherapeutic drug monitoring (TDM) peak and trough levels.19-24
Most of these studies show that both volume of distribution and
clearance increase in obese patients. Initially, total body weight
(TBW) was shown to be the best predictor for vancomycin clear-
ance.20,21 However, these findings have been challenged by other
studies conducted in obese patients, including the most
recent.19,22,24
As a consequence, the exact dosing strategy for vancomycin in
obese patients still remains to be established. This study aims to
quantify the PK of vancomycin in morbidly obese and nonobese
individuals. Using prospectively collected, rich data gathered over
48 h after a single dose in individuals over a wide range in body
weight, we aim to identify covariates that best predict changes in
vancomycin clearance and volume of distribution in obesity. The
model is externally validated using independent data and is ultimately
applied to guide vancomycin dosing in the (morbidly) obese, thereby
optimizing target attainment.
SMIT ET AL. 32 | METHODS
2.1 | Subjects
Morbidly obese patients with an indication for bariatric surgery
(BMI ≥40 kg m−2 or ≥35 kg m−2 with comorbidities), i.e. laparoscopic
sleeve gastrectomy or gastric bypass, and nonobese healthy volun-
teers (BMI 18–25 kg m−2) were considered for inclusion in this study.
Participants were excluded when they were known to have an allergy
to glycopeptides, were pregnant or breastfeeding, were renally
impaired (defined as estimated glomerular filtration rate of
<60 mL min−1 1.73 m−2 (calculated using the Cockcroft–Gault [CG]
formula with lean body weight [LBW] for obese25 or CG with TBW
for nonobese) or had used potentially nephrotoxic drugs (for example
aminoglycosides, loop diuretics, or nonsteroid anti‐inflammatory
drugs) in the week before surgery. All participants provided written
informed consent prior to inclusion. This clinical trial was approved
by the local human research and ethics committee (Medical Research
Ethics Committees United, Nieuwegein, The Netherlands,
NL52260.100.16) and registered in the Dutch Trial Registry
(NL5885/NTR6058), and was conducted in accordance with the prin-
ciples of the Declaration of Helsinki and Good Clinical Practice
guidelines.2.2 | Study design
Participants received a single intravenous infusion of vancomycin
(obese patients: 12.5 mg kg−1, maximum 2500 mg; nonobese
1000 mg as fixed dose, all infused in 10 mg min−1). Obese patients
received the infusion during or immediately after bariatric surgery.
Blood samples were collected 0.25, 0.5, 1, 1.5, 2, 3, 4, 6 and 12 h after
end of infusion. In the obese group, samples were also drawn during
infusion, at 2 and 0.25 h before end of infusion. Additional samples
were drawn around 24 h and, if the individual was still admitted,
48 h after start of infusion. Blood samples were collected in lithium‐
heparin tubes, centrifuged at 1900 g for 5 min, after which plasma
was stored at −80°C until analysis. For safety assessment, serum cre-
atinine was measured before and 24 h after administration of vanco-
mycin. Estimated glomerular filtration rate was calculated using
Modification of Diet in Renal Disease (MDRD) or Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD‐EPI) formulas, either the con-
ventional CG formula (CG‐TBW) or CG calculated with LBW instead
of TBW for obese (CG‐LBW). MDRD and CKD‐EPI were corrected
for body surface area (BSA) by multiplying the result (in mL min−1
1.73 m−2) by BSA/1.73. Lastly, 24‐h urine was collected on the study
day to measure 24‐h creatinine clearance as marker for the glomerular
filtration rate (GFR).2.3 | Sample assay
Vancomycin plasma concentrations were measured using a
validated, commercially available immune‐assay method (VANC3,Cobas System, Roche Diagnostics GmbH, Mannheim, Germany) with
a limit of detection (LOD) of 1.5 mg L−1, lower limit of quantification
(LLOQ) of 4 mg L−1 and upper limit of quantification of 80 mg L−1.
Measured concentrations below LOD or LLOQ were reported in
the dataset. Within‐run and interday variability was 3.7 and 4.4%,
respectively.2.4 | PK analysis
PK parameters were analysed using nonlinear mixed‐effects model-
ling (NONMEM 7.4, ICON Development Solutions, Hanover, USA)
and Pearl‐speaks‐NONMEM 4.8.126 using Pirana 2.9.7 (Certara
USA, Inc, Princeton, USA).27,28 One‐, 2‐ and 3‐compartmental models
were evaluated with the ADVAN 1, 3 or 11 routine, respectively,
using the first order conditional estimation method with interaction
and addition of the LAPLACIAN method. Interindividual variability
(IIV) and residual variability were assumed to be respectively log‐
normally and normally distributed. NONMEM output was visualized
with R 3.5.1 (Xpose package 4.6.1)29 and GraphPad Prism 6.0
(GraphPad Software, La Jolla, USA). Values below LOD were
analysed using the M3 method as described elsewhere.30 Model
building was performed in 3 stages: (1) selection of the structural
model, i.e. a 1‐, 2‐ or 3‐compartmental model, (2) selection of the
statistical error model (additive, proportional or a combined error
model) and (3) a covariate analysis. Nested models were compared
using the drop in objective function value (OFV, −2 log likelihood
function), where a difference of 3.84 corresponds with a P‐value
<.05 with 1 parameter difference. In addition, goodness of fit plots
(GOF), such as observed vs population and individual predictions, or
conditional weighted residuals vs time after dose or population
predictions were used for diagnostic purposes. Lastly, parameter
estimate precision, shrinkage, individual fits, and prediction‐corrected
visual predictive checks (pcVPC)31 were evaluated to identify the
best model.
Potential covariates were identified by assessing trends in plots of
the individual posthoc parameter or the unexplained variability
against the specific covariate. Covariates that were present in the
dataset included TBW, LBW (calculated using the Janmahasatian for-
mula32), adjusted body weight (ABW, calculated with correction fac-
tor 0.4 as described elsewhere33), BMI, ideal body weight (using the
Devine formula34), sex, age, GFR (based on collection of 24‐h urine)
and serum creatinine‐based estimations of GFR such as CG‐TBW,
CG‐LBW, MDRD or CKD‐EPI (the latter 2 both normalized for BSA
1.73 m2 and de‐indexed for BSA by multiplying the original value
by BSA/1.73). Covariates were implemented in the model using linear
and power functions, standardized for a typical individual of 70 kg or
median value of the covariate.35 Inclusion was considered when
step‐by‐step inclusion resulted in a drop in OFV of at least −3.84
(P < .05) and backward deletion gave an OFV increase of at least
10.8 points (P < .001). Furthermore, the contribution of a covariate
was judged based on the reduction in IIV and diagnostics
described earlier.
TABLE 1 Summary of baseline characteristics
Parameter
Morbidly obese group
(n = 20)
Nonobese group
(n = 8)
Weight (kg) 139.0 (110.6–234.6) 69.5 (60.0–84.7)
Height (cm) 173.5 (159–189) 182.5 (166–190)
BMI (kg m−2) 45.5 (40.8–65.7) 21.2 (20.4–25.0)
Age 38.0 (23–54) 25.5 (20–55)
Serum creatinine
(μmol L−1)a
72 (41–101) 70 (60–86)
GFR (mL min−1) 141.4 (80.7–260.7) 117.9 (88.1–147.0)
MDRD (mL min−1) 138.3 (89.5–220.6) 115.4 (72.8–144.7)
CKD‐EPI (mL min−1) 148.1 (95.5–221.6) 125.3 (77.1–139.3)
CG‐TBW (mL min−1) 249.2 (166.0–431.8) 140.1 (87.9–157.3)
CG‐LBW (mL min−1) 122.0 (83.1–191.0) 140.1 (87.9–157.3)
Data shown as median (range).
aSerum creatinine as measured before administration of vancomycin.
BMI, body mass index; GFR, glomerular filtration rate measured using 24‐h
creatinine clearance; MDRD, Modification of Diet in Renal Disease;
CKD‐EPI, Chronic Kidney Disease Epidemiology Collaboration; CG‐TBW,
Cockcroft–Gault (conventional); CG‐LBW, CG calculated with lean body
weight instead of total body weight for obese.
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The final model was internally validated by pcVPC based on 1000 sim-
ulations, split for obese and nonobese individuals. Parameter precision
and robustness of the structural and final model were analysed by the
sampling importance resampling procedure.36
2.6 | External validation
Data from a previously published prospective study in which 6 obese
(111–226 kg) and 4 nonobese (66–89 kg) individuals with normal renal
function received a single infusion of 1000 mg vancomycin in 40 min,21
were used to externally validate our PK (covariate) model. In the exter-
nal validation study, vancomycin concentrations were measured using
a validated immuno‐assay with a LLOQ of 0.5 mg L−1. External valida-
tion was done using pcVPC based on 1000 simulations, split for obese
and nonobese individuals. Bias and precision of the model was quanti-
fied by calculation of the median prediction error (MPE) and root mean
squared error (RMSE) according to equations (1) and (2),
PEi %ð Þ ¼ Cpred;i − Cobs;iCobs;i x 100% (1)
RMSE mg L−1
  ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑ Cpred;i−Cobs;i
 2
N
s
(2)
where PEi and RMSE are the prediction error for the ith observation
and root mean squared error of all observations, where Cpred,i and
Cobs,i represent the predicted and observed vancomycin concentration
for the ith observation and N is total number of observations. MPE
under 20% and RMSE under 5 mg L−1 were considered accurate.
2.7 | Simulation based comparison of dosing
strategies
To guide the optimal dosing strategy in the obese, simulations using the
final model with IIV were performed with different dose regimens in
10 000 obese individuals (BMI >35 kgm−2) with a uniformweight distri-
bution between 90 and 230 kg. AUC24hwas calculated by implementing
an AUC compartment equal to the central compartment in the
NONMEM $DES subroutine. Based on literature, we chose a target
for the probability of target attainment (PTA) and probability of toxicity
(PTOX) anAUC24h of >400mgh L
−1 andAUC24h > 700mg h L
−1, respec-
tively, both assessed at day 3 (when in steady state).We aimed for a PTA
of at least 90% in obese individuals (BMI > 35 mg kg−2) with the lowest
possible PTOX, as recommended by the European Medicine Agency.
Simulated dose regimens consisted of continuous infusion regimens of
20, 25, 30, 35, 40 and 45 mg kg−1 day−1 (with or without a dose cap
for the 24‐h dose) and 2000, 3000, 4000, 5000 and 6000 mg day−1 as
fixed doses. In combination with the selected dose, loading doses of
500, 1000, 1500, 2000 or 2500 mg were evaluated. The loading doses,
given as single infusions at a rate of 10 mg min−1, were followed by a
continuous infusion starting 2 h after start of the loading dose. Differentloading dose strategieswere evaluated by comparing themean and95%
confidence intervals of the AUC24h‐ratio per weight group, which is cal-
culated by dividing the AUC24h at day 1 by the AUC24h at day 3. Ideally,
the 95% confidence intervals of these ratios should contain 1, meaning
that steady state is reached at day 1 and the loading dose is adequate.2.8 | Correlation of trough concentrations with
achievement of target AUC24h
For the selected vancomycin dose, trough concentrations related to
the optimal target attainment (AUC24h within the target of
400–700 mg h L−1) were investigated by simulations using the same
weight distribution (n = 10 000). Administration of the dose over 2
or 3 administrations day−1 or a continuous infusion were investigated.
At day 3, trough concentrations that corresponded to the 2.5–95 per-
centiles of the AUC24h within the target of 400–700 mg h L
−1 were
identified. This target AUC24h was chosen since the current consensus
guideline describes that the recommended target trough concentra-
tions correspond to AUC24h > 400 mg h L
−1.13 Correlation between
trough concentrations and AUC24h at day 3 was assessed by linear
regression using R 3.5.1.3 | RESULTS
In total, 20 obese individuals with a median weight of 139.0 kg (range
110.6–234.6 kg) and 8 nonobese individuals with a median weight of
69.5 kg (range 60.0–84.7 kg) were included. Participant demographics
are shown in Table 1. A total of 326 samples was collected (238 in
obese and 88 in nonobese individuals), with a median of 12 samples
SMIT ET AL. 5(range 11–13) per participant. Twenty‐four samples (7%) were below
LOD and handled according to the M3 method.30 Samples were col-
lected up to 24 h in all cases. For 2 obese patients and all nonobese
individuals vancomycin concentrations were obtained until 48 h after
dosing. Measured vancomycin concentrations vs time are shown in
Figure A1 in the appendix.3.1 | PK analysis
A 3‐compartment model with first order elimination and a combined
proportional and additive residual error model with IIV for clearance,TABLE 2 Pharmacokinetic parameter estimates of the structural and fina
Parameter
Structu
(RSE %
CL (L h−1) 7.32 (1
CL70kg × TBW70
 θ1
CL70kg (L h
−1) ‐
θ1 ‐
V1 (L) 15.8 (2
V136.5yr ×(1 + θ2 * (Age − 36.5))
V136.5yr (L) ‐
θ2 ‐
QV1‐V2 (L h
−1) 16.2 (2
V2 (L) 13.2 (2
V270kg;36.5yr ×
TBW
70
 
× 1þθ2*ðAge − 36:5ð ÞÞ
 
V270kg;36.5yr (L) ‐
θ2 ‐
QV1‐V3 (L h
−1) 4.37 (2
V3 (L) 19.7 (2
Interindividual variability (%) a,b
CL 31.9 (2
CLnonobese ‐
CLobese ‐
V1 56.8 (4
V2 37.1 (3
Residual error
Proportional errorc,d 0.0401
Additive error (mg L−1)d 1.03 (5
OFV 682.82
aShrinkage of interindividual variability in the final model are below 20% for al
bCalculated by
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
eω2 − 1:
 q
cProportional error is shown as σ
dEpsilon shrinkage for the final model is 8%.
CL, clearance; V1, volume of distribution of central compartment; V2, volume
peripheral compartment 3; QV1‐V2, intercompartmental clearance between V1
total body weight; OFV, objective function value; RSE, relative standard error
obtained from sampling importance resampling procedure.V1 and V2 best described the data. Parameters of the structural model
are shown in Table 2.
Implementation of TBW with a linear relationship on V2 gave the
largest reduction in OFV (−24.5; P < .001) and IIV (from 37.1 to
5.8%). In the model with TBW on V2, IIV on V2 was omitted from
the model since this did not impact the OFV (+0.11). In the following
step, the best results were obtained by inclusion of (1) TBW with a
power function on clearance using an estimated exponent, (2) ABW
and (3) LBW, both with linear functions. This resulted in OFV reduc-
tions of −17.4 (1), −18.9 (2) and −15.5 (3; P < .001 for all), resulting
in a reduction in IIV from 29.3% to 21.2, 20.5 and 21.9%, respectively.
No significant differences were visible in GOF plots between TBW,l (covariate) model
ral model
) [95% CI]
Final model (RSE %)
[95% CI]
4.0) [6.13–8.33] ‐
5.72 (5.0) [5.34–6.10]
0.535 (20) [0.36–0.67]
7) [11.2–20.4] ‐
16.7 (18) [12.9–21.2]
0.0136 (31) [0.00575–0.0211]
0) [13.0–21.4] 15.8 (23) [11.6–21.7]
6) [9.48–17.2] ‐
6.98 (17) [5.78–8.67]
0.0136 (31) [0.00575–0.0211]
5) [2.88–6.07] 5.21 (21) [3.83–6.63]
1) [14.9–26.3] 19.5 (13) [15.0–24.1]
2) [25.3–41.6] ‐
5.28 FIX
24.7 (19) [18.4–32.3]
4) [40.1–83.9] 45.3 (24) [34.9–62.0]
7) [23.4–50.9] ‐
(21) [0.0253–0.0568] 0.0392 (21) [0.0246–0.0541]
.0) [0.923–1.13] 1.07 (5.0) [0.960–1.16]
609.89
l estimates
of distribution of peripheral compartment 2; V3, volume of distribution of
and V2; QV1‐V3, intercompartmental clearance between V1 and V3; TBW,
based on covariance step in NONMEM; 95% CI, 95% confidence interval
6 SMIT ET AL.LBW and ABW‐models. Since TBW is more readily available in clinical
practice and is therefore preferable in the light of model‐informed
dose recommendations, we chose to includeTBW on clearance. Inclu-
sion of MDRD, CKD‐EPI, CG‐TBW, CG‐LBW or GFR (based on 24‐h
creatinine clearance) did not significantly improve the model
(P > .001). After inclusion of TBW on clearance, no remaining covari-
ates could be identified for this parameter. Lastly, introduction of
age as covariate on V1 and V2 resulted in a decrease of OFV with
−19.4 points and improved GOF (P < .001).
Since IIV for clearance appeared to be significantly higher in the
obese group, we estimated separate IIV values for both groups,
resulting in an OFV drop of −11.8 and a resulting IIV on clearance of
5.3% and 24.7% for nonobese and obese subpopulations, respectively.
While the IIV on clearance in the nonobese showed a high uncertainty
and significant shrinkage, we decided to fix this parameter to 5.3% in
the final model, since removing it from the model resulted in a penalty
of 4 points increase in OFV. The final PK parameters of the resultingFIGURE 1 Prediction‐corrected visual predictive checks (pcVPC) of the f
panel) subgroups of the current study. The observed concentrations are sh
observed data are shown as solid, lower and upper dashed lines. Grey sha
grey) and 2.5th and 97.5th percentiles (light grey) of simulated concentratio
(LOD) is depicted by the dotted grey line. Intervals of the bins are shown
observed proportion below the LOD (dashed line), where shaded areas repr
(n = 1000)model are shown in Table 2. GOF plots for the final model are shown
in Figure A2.
3.2 | Internal validation
The pcVPC, shown in Figure 1 shows that the median and 2.5th and
97.5th percentiles of the prediction intervals correspond with the
observations. The lower panel in Figure 1 shows that the model per-
forms well in predicting the portion of observations that are below
LOD. Confidence intervals of the model parameters based on the sam-
pling importance resampling procedure are presented in Table 2.
3.3 | External validation
The pcVPCs of the external validation using data of the study from
Blouin and colleagues (6 obese and 4 nonobese individuals) are shown
in Figure 2. The VPC shows a good predictive performance of ourinal model split for nonobese (upper left panel) and obese (upper right
own as black circles, median, 2.5th and 97.5th percentiles of the
ded areas represent the 95% confidence intervals of the median (dark
ns (n = 1000) based on the original dataset. The lower limit of detection
by the vertical ticks on the top of the plot. Lower panels show the
esent the 95% confidence intervals based on simulated concentrations
FIGURE 2 Prediction‐corrected visual predictive checks (pcVPC) of the final model split for nonobese (upper left panel) and obese (upper right
panel) subgroups for the external dataset published by Blouin et al.21 The observed concentrations from the Blouin study are shown as black
circles, median, 2.5th and 97.5th percentiles of the observed data are shown as solid, lower and upper dashed lines. Grey shaded areas represent
the 95% confidence intervals of the median (dark grey) and 2.5th and 97.5th percentiles (light grey) of simulated concentrations (n = 1000) based
on the original dataset. The lower limit of quantification (LOQ) is depicted by the dotted grey line. Intervals of the bins are shown by the vertical
ticks on the top of the plot. Intervals of the bins are shown by the vertical ticks on the top of the plot. Lower panels show the observed proportion
below the LOQ (dashed line), where shaded areas represent the 95% confidence intervals based on simulated concentrations (n = 1000)
SMIT ET AL. 7model in the obese population without significant bias and good pre-
cision, while the model seems to slightly underpredict observations
in nonobese individuals, mostly in higher concentrations (>20 mg L−1).
This is shown by MPE and RMSE, where acceptance criteria
(MPE < 20%, RMSE <5 mg L−1) are met only in the obese population
(MPE for nonobese subgroup: −20.1%, obese subgroup: −0.171%, cor-
responding RMSE values 7.24 mg L−1 for the nonobese and 3.27 mg L−1
for the obese population).3.4 | Simulation based comparison of dosing
strategies
Figure 3 shows the results of simulations in obese individuals ranging
90–230 kg upon weight‐based dose regimens. In Figure 3, the left col-
umn shows the resulting mean AUC24h with 95% percentiles, while in
the right column PTA (AUC24h > 400) and PTOX (AUC24h > 700) atday 3 are presented. Figure A3 in the appendix shows the same plot
for fixed dose regimens. Figure 3 shows that when the vancomycin
dose is increased from 25 mg kg−1 day−1 to 45 mg kg−1 day−1, both
chances of achieving an AUC24h > 400 and > 700 increase for all indi-
viduals. A high PTA could be achieved for all body weights using a
dose regimen of 35 mg kg−1 day−1, maximized at 5500 mg day−1.
For some weight categories where the PTA (AUC24h > 400) was below
90% (i.e. individuals <110 kg and >210 kg), PTA was still >80%, and in
all cases the probability of reaching an AUC24h > 350 mg h L
−1 was
above 90% (data not shown). The highest PTOX
(AUC24h > 700 mg h L
−1) with this dose regimen is seen in individuals
weighing around 150–160 kg. Notably, in this group still 94% of the
individuals have an AUC24h < 900 mg h L
−1. A fixed dose of
2000 mg day−1, the recommended dose in the FDA drug label, results
in unacceptably low PTA for both nonobese and obese individuals
(Figure A3, appendix). All weight‐based dosages evaluated in
Figure 3 were maximized at 5500 mg day−1, based on Monte Carlo
FIGURE 3 Twenty‐four‐hour area under the curve (AUC) values at day 3 (left column) and probability of target attainment (PTA, AUC24h > 400)
or toxicity (PTOX, AUC24h > 700) (right column), shown vs weight (90–230 kg) for several dose regimens (n = 10 000 per dose regimen). (A–E)
Increasing dose regimens from 25 mg kg−1 day−1 to 45 mg kg−1 day−1, all maximized at 5500 mg day−1. In the left plots, the solid black line and
grey area indicate mean observed AUC with 2.5–97.5 percentiles. Dashed grey line represents target AUC levels (400 and 700 mg h L−1). In the
right plots, the dashed green line and dot‐dashed red line indicate PTA and PTOX, respectively. Dashed grey lines represent the threshold for PTA
(0.9) and, for reference, 20% PTOX (0.2). AUC, 24 h area under the curve at day 3; PTA, probability of target attainment (AUC > 400 mg h L−1) at
day 3; PTOX, probability of toxicity (AUC > 700 mg h L−1) at day 3
8 SMIT ET AL.simulations with fixed dosages (Figure A3 in the appendix) where a
suboptimal PTA (AUC24h > 400) is seen with dosages ≤5000 mg
day−1, and considerable PTOX (AUC24h > 700) is seen with high body
weights with 24‐h dosages ≥6000 mg. Figure 4 shows simulationswith increasing loading doses in combination with a maintenance dose
of 35 mg kg−1 day−1 illustrating that a loading dose of 1500 mg yields
similar exposure at day 1 compared to day 3 without significant trends
across body weights, with all mean AUC‐ratio's close to 1 and all
FIGURE 4 Mean ratio of AUC24h at day 1/AUC24h at day 3 with 95% confidence intervals, shown for different loading doses vs body weight
(90–230 kg), based on Monte Carlo simulations (n = 10 000 per loading dose). Each line represents 1 loading dose regimen. All individuals
received 35 mg kg−1 continuous infusion started 2 h after the loading dose (maximised at 5500 mg day−1). Grey dashed line represents a ratio of 1.
AUC, 24‐h area under the curve
SMIT ET AL. 9corresponding 95% confidence intervals containing 1. No clinically sig-
nificant influence of age on simulated vancomycin concentrations was
found for 4 typical individuals with age ranging 20–50 years and a
TBW of 130 kg (Figure A4 in appendix).3.5 | Correlation of trough concentrations with
achievement of target AUC24h
A daily dose of 35 mg kg−1, maximized at 5500 mg day−1, was selected
for simulation of trough concentrations at day 3 when given as inter-
mittent or continuous infusion regimens. Figure 5 shows the AUC24h
vs trough concentrations for obese individuals at day 3. There is a
strong relationship between AUC at day 3 and trough concentrations,
with R2 values of 0.92, 0.93 and 1.00 when the dose is given in 2‐ or
3‐times dosages or as continuous infusion, respectively. Trough
concentrations corresponding to 95% AUC24h within target (400–
700 mg h L−1) are 5.70–14.6 (dose divided over 2 administrations),
7.8–17.8 (dose divided over 3 administrations) and 17.5–28.3 (contin-
uous infusion) mg L−1, as depicted by the red lines in Figure 5.4 | DISCUSSION
Our study shows that vancomycin PK is significantly altered by obe-
sity. We found that in obese individuals up to 235 kg without renal
impairment, vancomycin clearance could be predicted by TBW
(Table 2) using a power function with estimated exponent of 0.54,
which was confirmed by the external validation. Monte Carlo simula-
tions incorporating IIV showed that in obese individuals, the target
exposure (at least 90% AUC24h > 400) could be attained when vanco-
mycin is dosed as 35 mg kg−1 day−1, maximized on 5500 mg day−1.Using this regimen, PTOX (AUC24h > 700) was <20% for most individ-
uals, despite a slight trend in increasing exposure with increasing body
weight. In theory, a dose regimen based on TBW scaled to 0.54 (in
accordance with the relationship found between CL and TBW) would
result in an equal exposure across body weights, but is in our opinion
less suitable for use in daily practice. For continuous infusion regimens
of 35 mg kg−1 day−1, a loading dose of 1500 mg is sufficient for
reaching steady at day 1 for all weight categories. A fixed dose regi-
men of 2000 mg day−1 as dictated by the FDA drug label, leads to
unacceptable low PTA under 25% across the whole population, as
was described earlier.13
A strong aspect of our study is the prospective study design with
intensive PK sampling in adults with a wide range of body weights
across the included cohort from 60 to 235 kg, allowing for the charac-
terisation of a 3‐compartment model. This is in contrast with other
reports on vancomycin PK in obesity, that fully rely onTDM data, that
consist mostly of peak and trough concentrations, making it difficult to
estimate >1 compartment, thereby limiting the ability to adequately
assess individual PK parameters.19,22 Moreover, we used data from a
previously performed study to externally validate our model.21 Our
model showed a high precision without bias in describing the data in
the obese subgroup. Therefore, taken these results together with
our internal validation, we can conclude that our PK‐model shows an
excellent performance in predicting vancomycin PK in the (morbidly)
obese population up to 235 kg.
Our results on vancomycin clearance and volume of distribution in
obese individuals puts forward what was known on vancomycin PK in
obesity. Regarding clearance, predominantly retrospective studies also
found a larger vancomycin clearance in obese compared to nonobese
individuals.19,20,22,24 One prospective rich sampling PK study in
healthy obese individuals, similar to our study design but with only 6
FIGURE 5 Twenty‐four‐hour area under the curve (AUC24h) at day 3
vs individual trough concentrations at day 3 (measured 0,5 h prior to
the second dose) based on Monte Carlo simulation in obese patients
(n = 10 000, weight ranging 90–230 kg), using the final model.
Vancomycin dose was 35 mg kg−1 day−1, maximized at 5500 mg day−1,
given over 2 infusions day−1 (A), 3 infusions day−1 (B) or as a
continuous infusion regimen (C). Each dot represents 1 simulated
individual. Dashed horizontal lines show the target AUC window
(400–700 mg h L−1). Trough concentrations corresponding to 95% of
AUC24h within this target are shown with red vertical lines. The black
line represents the linear regression line, with corresponding adjusted
R2 value shown in the graph
10 SMIT ET AL.obese individuals included, found a linear relationship of TBW with
vancomycin clearance, in contrast to the power relationship as found
in our study.21 One retrospective study in 108 obese and 596nonobese patients, found no difference in absolute vancomycin clear-
ance between both groups.23 This might be explained by the relatively
low body weight in the obese group (mean TBW 94.3 kg). Other
reports in which obese patients were included, show conflicting
results on the best predictive covariate for vancomycin clearance,
varying from CG with TBW,19 serum creatinine,24 or a combination
of serum creatinine, age, TBW and sex.22 These results might be
explained by differences in studied body weights or employed sam-
pling schedules (i.e. use of TDM data vs intensive sampling). Consider-
ing the fact that vancomycin is predominantly excreted renally, it is
interesting that we found TBW to be a better predictor than any of
the renal function estimates including GFR based on 24‐h urine clear-
ance. This might be explained by the lack of individuals with renal
impairment in our study. In addition, in our PK model vancomycin
clearance of a typical individual of 70 kg is 5.72 L h−1, corresponding
to 95 mL min−1, which is slightly below the average GFR in our rela-
tively young population. This is in line with what has been reported
in other studies and suggests that other processes besides glomerular
filtration also play a role.6 There is substantial evidence that obesity
can influence both passive and active processes in the kidneys,37
which might explain why body weight is a better predictor for vanco-
mycin clearance than renal function estimates in obese individuals
without renal failure.
Results on vancomycin volume of distribution in obese seem to be
more consistent across literature. Five studies reported on changes in
volume of distribution, all describing an increase of volume of distribu-
tion with body weight in a linear fashion.19-21,23,24 No study reported
age as a covariate for volume of distribution. In our study we found
age as covariate for volume of distribution, even though its impact
was limited. As a consequence, increasing age does not impact the
proposed dose regimen.
It is well known that vancomycin PK exhibits large IIV and has a
small therapeutic window, and therefore the 2009 consensus guideline
recommends that TDM is routinely applied when treating patients with
vancomycin.13 Our results further substantiate this recommendation
for the obese populations, since our final PK model still shows consid-
erable unexplained IIV for both clearance (25% in the obese subgroup)
and volume of distribution (45% on V1). To obtain an adequate AUC24h
between 400 and 700 mg h L−1, guidelines recommend to target
trough concentrations between 15–20 mg L−1.13 We show that in
obese individuals, steady state trough concentrations of 5.7–-
14.6 mg L−1 (when dosed 2 times daily) are sufficient to assure ade-
quate exposure. This discrepancy with the guideline recommendation
has been reported for several other special populations as well.14,15
Plots with individual posthoc clearance and volume of distribution
values visualized by colour (shown in Figure A5 in the appendix) point
out that the variability in volume of distribution explains why we see
this range in trough concentrations with similar AUC24 values. To cir-
cumvent this problem in translating trough concentrations to expo-
sure, it might be preferable to measure the AUC directly using a
limited sampling strategy (for example with peak‐and‐trough concen-
trations) along with the employment of Bayesian forecasting software.
This recommendation has also been incorporated in the revision of the
SMIT ET AL. 112009 vancomycin TDM guideline, which is currently under develop-
ment.38 If resources or knowledge is unavailable, clinicians should be
aware that in obese individuals, trough concentrations below 15mg L−1
do not necessarily correspond to a subtherapeutic exposures and
therefore do not always require dose adjustments.
Some limitations apply to our study. First, our participants received
only a single vancomycin infusion. Therefore, extension of our PK
model to simulate continuous infusions should be done with caution.
However, the maintenance dose is merely dependent on vancomycin
clearance which can be adequately estimated in the current study
design. Second, in interpreting the simulations, we chose a target
PTA of 90% for selection of the best dose regimen, as advocated by
the EMA.39 However, certain situations may call for a higher target
PTA and therefore a higher dosage, for example in serious life‐
threatening infections.39,40 In addition, the target for PTA
(AUC24 > 400 mg h L
−1), has only been established for S. aureus infec-
tions. We still remain fairly ignorant as to the appropriate targets for
other infections where vancomycin is indicated. Third, obese individ-
uals underwent bariatric surgery during the PK study, which could the-
oretically interfere with the results. However, the concerning
operations are performed laparoscopically, with a short duration
(<1 h), and minimal blood loss (<50 mL). Therefore, we consider this
influence to be negligible. Last, the participants in our study were,
besides being obese, otherwise healthy individuals with adequate
renal function. Therefore, one should apply caution in extrapolating
of our results to individuals with renal impairment or critical illness
and always perform TDM in these populations.
In conclusion, our study shows that in order to obtain optimal expo-
sure with minimal risk on toxicity, vancomycin should be dosed as
35 mg kg−1 day−1 in obese individuals without renal impairment. For
continuous infusion regimens, a loading dose of 1500 mg is sufficient
for the whole population to obtain steady state at day 1.
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SMIT ET AL. 13APPENDIX AFIGURE A2 Goodness‐of‐fit plots of the final pharmacokinetic model for nonobese individuals
FIGURE A1 Measured vancomycin concentration vs time after infusion
FIGURE A3 Simulation based comparison of 24‐h area under the curve (AUC) values at day 3 and probability of target attainment (PTA) or
toxicity (PTOX) for fixed dose regimens
FIGURE A4 Predicted vancomycin concentration when administered to 4 individuals with a weight of 130 kg and varying age (20–50 years)
after administration of a 1500 mg vancomycin dose (infusion rate 10 mg min−1) followed after 2 h by a continuous infusion of 35 mg kg−1 day−1
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FIGURE A5 Twenty‐four‐hour area under
the curve (AUC24h) at day 3 vs individual
trough concentrations at day 3 based on
Monte Carlo simulation in obese patients,
using the final model, coloured by individual
body weight, volume of distribution (V1) and
clearance (CL)
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